知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.015 秒)

    Anti-edema agent
    2.
    发明授权
    Anti-edema agent 失效
    抗水肿剂

    公开(公告)号：US06238665B1

    公开(公告)日：2001-05-29

    申请号：US09434495

    申请日：1999-11-05

    申请人： Mitsuru Naiki

    发明人： Mitsuru Naiki

    IPC分类号： A61K39395

    CPC分类号： A61K31/415 ,  A61K39/395 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising a pharmaceutically effective amount of histamine-added immunoglobulin substantially suppresses edema formation and an increase of vascular permeability of the blood-brain barrier. The histamine-added immunoglobulin may be administered with a high degree of safety and a low incidence of side effects. The histamine-added immunoglobulin and pharmaceutical compositions containing it may be used for treatment and prevention of edema, edema formation, and an increase of vascular permeability of the blood-brain barrier.

    摘要翻译： 包含药学有效量的组胺加入的免疫球蛋白的药物组合物基本上抑制血脑屏障的水肿形成和血管通透性的增加。 可以以高度的安全性和低的副作用发生施用组胺加免疫球蛋白。 含有组胺的免疫球蛋白和含有它的药物组合物可用于治疗和预防血脑屏障的水肿，水肿形成和血管通透性的增加。

    ANALGESIC
    4.
    发明申请
    ANALGESIC 审中-公开

    公开(公告)号：US20130296426A1

    公开(公告)日：2013-11-07

    申请号：US13979723

    申请日：2012-01-30

    申请人： Munekazu Iinuma ,  Shoei Furukawa ,  Mitsuru Naiki ,  Tomoyuki Okada ,  Tomonori Matsumoto ,  Kazuyoshi Sawada

    发明人： Munekazu Iinuma ,  Shoei Furukawa ,  Mitsuru Naiki ,  Tomoyuki Okada ,  Tomonori Matsumoto ,  Kazuyoshi Sawada

    IPC分类号： A61K31/23 ,  A61K31/231

    CPC分类号： A61K31/23 ,  A61K31/231

    摘要： An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.

    摘要翻译： 本发明的目的是提供一种有效预防或治疗各种疼痛疾病的止​​痛剂。 本发明提供一种含有C10脂肪酸的酯作为活性成分的止痛剂。 含有该化合物作为活性成分的本发明的止痛剂作为各种疼痛疾病例如由骨关节炎（例如膝关节骨性关节炎和髋关节骨性关节炎）引起的疼痛或脱髓鞘性疾病如多发性硬化症的预防或治疗剂是非常有用的 或吉兰 - 巴雷综合征。

    Therapeutic agent for intractable vasculitis
    5.
    发明授权
    Therapeutic agent for intractable vasculitis 失效
    难治性血管炎治疗剂

    公开(公告)号：US06251929B1

    公开(公告)日：2001-06-26

    申请号：US09434494

    申请日：1999-11-05

    申请人： Mitsuru Naiki ,  Takumi Numazawa ,  Tomoyuki Okada ,  Kazuharu Ienaga ,  Kazuyoshi Sawada

    发明人： Mitsuru Naiki ,  Takumi Numazawa ,  Tomoyuki Okada ,  Kazuharu Ienaga ,  Kazuyoshi Sawada

    IPC分类号： A64K31415

    CPC分类号： A61K31/4166

    摘要： A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1, and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.

    摘要翻译： 用于顽固性血管炎的恶性类风湿性关节炎的高度安全的治疗剂含有式（I）表示的乙内酰脲衍生物或其药学上可接受的盐作为有效成分：其中R1和R2可以相同或不同 表示氢，烷基或环烷基; X和Y各自可以相同或不同，表示氢，羟基，烷基或烷氧基，或X和Y一起表示氧代基。 乙内酰脲衍生物显着抑制模型动物（MRL / lpr）中天然发育的关节炎和动脉炎（皮肤溃疡和耳廓梗塞坏死）的产生，并进一步显着延长MRL / lpr小鼠的存活率。 因此，具有低毒性和少量副作用的乙内酰脲衍生物作为难治性血管炎如恶性类风湿性关节炎的高度安全的治疗剂是非常有用的。

    Activated immunoglobulin
    8.
    发明授权
    Activated immunoglobulin 失效
    活化免疫球蛋白

    公开(公告)号：US06627194B1

    公开(公告)日：2003-09-30

    申请号：US08694315

    申请日：1996-08-08

    申请人： Haruo Yoshii ,  Mitsuru Naiki ,  Yuriko Fukata

    发明人： Haruo Yoshii ,  Mitsuru Naiki ,  Yuriko Fukata

    IPC分类号： A61K39395

    CPC分类号： C07K16/18 ,  A61K38/00 ,  Y10S424/81 ,  Y10S530/868

    摘要： Activated immunoglobulin which is useful as an eosinophilia-suppressing agent, immunomodulating agent, therapeutic agent for autoimmune diseases, anfiinflammatory agent and antiallergic agent is obtained by admixing immunoglobulin with a histamine component and then substantially or completely removing the histamine component. The histamine component may be removed or separated by dialysis, gel filtration, adsorption chromatography, ion exchange chromatography, or affinity chromatography. The method imparts pharmacological activity which is not inherently available in immunoglobulin of the natural type to immunoglobulin. The activated immunoglobulin of the present invention has an immunomodulating action which is clearly different from that of conventional immunosuppressive agents. It is useful as a therapeutic agent for autoimmune diseases such as chronic rheumatoid arthritis, systemic lupus erythematodes and multiple sclerosis as well as for various immunodeficiency syndromes wherein the immune system is not functioning properly. The activated immunoglobulin of the present invention may be also used as a pharmaceutical agent for eosinophilia caused by infectious diseases, parasitic diseases, diseases of respiratory organs, autoimmune diseases, malignant tumors, etc. In addition, the product of the invention may be used as an excellent antiinflammatory agent and antiallergic agent, and so is highly useful as a pharmaceutical.

    摘要翻译： 通过将免疫球蛋白与组胺成分混合，然后基本上或完全除去组胺成分，得到可用作嗜酸性粒细胞增多抑制剂，免疫调节剂，自身免疫性疾病治疗剂，抗炎药和抗过敏药物的活性免疫球蛋白。 组胺组分可以通过透析，凝胶过滤，吸附色谱，离子交换层析或亲和层析来去除或分离。 该方法赋予在天然免疫球蛋白免疫球蛋白免疫球蛋白中本身不具有的药理学活性。 本发明的活化免疫球蛋白具有与常规免疫抑制剂明显不同的免疫调节作用。 它可用作自身免疫疾病如慢性类风湿性关节炎，系统性红斑狼疮和多发性硬化以及各种免疫缺陷综合征的治疗剂，其中免疫系统不能正常运作。 本发明的活化免疫球蛋白也可以用作由感染性疾病，寄生虫病，呼吸器官疾病，自身免疫性疾病，恶性肿瘤等引起的嗜酸性粒细胞增多的药剂。此外，本发明的产品可以用作 优异的抗炎剂和抗过敏剂，因此作为药物是非常有用的。

    Furanone derivatives for the suppression or treatment of autoimmune diseases
    9.
    发明授权
    Furanone derivatives for the suppression or treatment of autoimmune diseases 失效
    呋喃酮衍生物用于抑制或治疗自身免疫性疾病

    公开(公告)号：US5532271A

    公开(公告)日：1996-07-02

    申请号：US301398

    申请日：1994-09-08

    申请人： Mitsuru Naiki ,  Yuichi Takeoka ,  Seishi Suehiro

    发明人： Mitsuru Naiki ,  Yuichi Takeoka ,  Seishi Suehiro

    IPC分类号： A61K31/365 ,  A61K31/34

    CPC分类号： A61K31/365

    摘要： The present invention relates to a method for preventing or treating autoimmune diseases in a mammal which comprises administering to the mammal an effective amount of at least one furanone derivative of the formula (I): ##STR1## wherein X is hydrogen, hydroxy, a lower alkyl group or a lower alkylene group; Y is hydrogen, hydroxy or a lower alkyl group; Z is hydrogen, a lower alkyl group or a lower hydroxyalkyl group; and the broken line represents the presence or absence of a second bond;or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及一种用于预防或治疗哺乳动物中的自身免疫性疾病的方法，其包括对哺乳动物施用有效量的至少一种式（I）的呋喃酮衍生物：其中X是氢，羟基 ，低级烷基或低级亚烷基; Y是氢，羟基或低级烷基; Z是氢，低级烷基或低级羟烷基; 虚线表示存在或不存在第二键; 或其药学上可接受的盐。

    Furanone derivatives for the treatment of inflammation
    10.
    发明授权
    Furanone derivatives for the treatment of inflammation 失效
    呋喃酮衍生物用于治疗炎症

    公开(公告)号：US5376682A

    公开(公告)日：1994-12-27

    申请号：US950563

    申请日：1992-09-25

    申请人： Mitsuru Naiki ,  Yuichi Takeoka ,  Seishi Suehiro

    发明人： Mitsuru Naiki ,  Yuichi Takeoka ,  Seishi Suehiro

    IPC分类号： A61K31/365 ,  A61K31/34

    CPC分类号： A61K31/365

    摘要： The present invention relates to a method for reducing or treating inflammation in a mammal which comprises administering to the mammal an effective amount of at least one furanone derivative of the formula (I): ##STR1## wherein X is hydrogen, hydroxy, a lower alkyl group or a lower alkylene group; Y is hydrogen, hydroxy or a lower alkyl group; Z is hydrogen, a lower alkyl group or a lower hydroxyalkyl group; and the broken line represents the presence or absence of a second bond; or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及一种用于减少或治疗哺乳动物炎症的方法，其包括向哺乳动物施用有效量的至少一种式（I）的呋喃酮衍生物：其中X是氢，羟基， 低级烷基或低级亚烷基; Y是氢，羟基或低级烷基; Z是氢，低级烷基或低级羟烷基; 虚线表示存在或不存在第二键; 或其药学上可接受的盐。